



## Leukemia

Guest Editor:

**Prof. Dr. Charles H. Lawrie**

Lymphoid Malignancy Research  
Group, Nuffield Department of  
Clinical Laboratory Sciences,  
University of Oxford, John  
Radcliffe Hospital, Oxford OX3  
9DU, UK

Deadline for manuscript  
submissions:  
**closed (31 July 2012)**

### Message from the Guest Editor

Dear Colleagues,

Leukemia (leukaemia- British spelling) is a malignancy of the blood originating from immature leukocytes (lymphoid and myeloid). It is the most common form of childhood cancer (~1/3 of cases) and accounts for >44,000 new diagnoses and >22,000 mortalities annually in the US alone. Recent advances in both laboratory and clinic continue to improve the outcome for patients. This special edition of *Cancers* gives an opportunity to describe recent original research in the field of leukemia, the development or application of new platforms or insights, and/or reviews of the field. We are particularly interested in genomics, leukemia stem cell research, novel therapeutics, epidemiological studies and new biomarker studies. If you would like to discuss an idea for a paper before committing please contact the guest editor.

Dr. Charles Lawrie  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)